GRTX Archives - Page 6 of 7

1 minute read

Why Is Galera Therapeutics Stock Sinking Today?

August 10, 9:45 AM

The FDA issued a Complete Response Letter (CRL) to Galera Therapeutics Inc's (NASDAQ: GRTX) New Drug Application (NDA) for avasopasem manganese (avasopasem) for radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer undergoing

GRTX

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

August 10, 9:06 AM

Gainers PHAXIAM Therapeutics (NASDAQ:PHXM) stock rose 36.4% to $0.6 during Thursday’s pre-market session. The market value of their…

ATNF

2 minute read

Why AppLovin Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket

By Lisa Levin

August 10, 8:06 AM

Gainers PHAXIAM Therapeutics S.A. (NASDAQ: PHXM) shares surged 46.7% to $0.64 in pre-market trading after gaining 6% on Wednesday.

AMRS

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

August 9, 5:32 PM

Gainers Vistagen Therapeutics (NASDAQ:VTGN) stock rose 22.5% to $8.62 during Wednesday’s after-market session. Trading volume for this security…

ACGN

4 minute read

Galera Receives Complete Response Letter From U.S. FDA for Avasopasem Manganese; The Co Intends To Request A Type A Meeting With The FDA To Understand The FDA’s Rationale For Its Decision

By Happy Mohamed

August 9, 4:35 PM

The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its cash runway and

GRTX

2 minute read

News

Pancreatic Cancer Action Network Urges Advocates From All 50 States To Call On Congress To Increase Federal Funding For Pancreatic Cancer Research

By Benzinga Newsdesk

June 14, 9:13 AM

Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June 14, 2023 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer patient

ARAV

2 minute read

Galera Announces FDA Orphan Drug Designation Granted To Rucosopasem For Pancreatic Cancer

By Benzinga Newsdesk

May 18, 8:07 AM

Galera Therapeutics, Inc. (NASDAQ: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that the U.S.

GRTX

1 minute read

Galera To Present 1-Year Reductions In Cisplatin-Related Chronic Kidney Disease Data From ROMAN Trial At 2023 American Society Of Clinical Oncology Annual Meeting

By Happy Mohamed

April 26, 10:01 AM

Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform

GRTX

5 minute read

Watching Galera Therapeutics; Traders Circulate TipRanks Note Suggesting “Poised For A Massive Rally”

By Happy Mohamed

March 8, 10:57 AM

https://blog.tipranks.com/these-2-strong-buy-penny-stocks-are-poised-for-a-massive-rally-say-analysts/ For investors, the stock market is always a game of risk and reward, and no segment exemplifies that better than

GRTX

1 minute read

Piper Sandler Initiates Coverage On Galera Therapeutics with Overweight Rating, Announces Price Target of $6

By Benzinga Newsdesk

February 21, 6:06 AM

Piper Sandler analyst Edward Tenthoff initiates coverage on Galera Therapeutics (NASDAQ:GRTX) with a Overweight rating and announces Price Target of $6.

GRTX

Feed Symbols: GRTX